Sunshine Heart’s cardiac medical device, the C-Pulse, has shown promise in a clinical trial, and the company plans to apply for pre-market approval sometime in the fourth quarter. The C-Pulse system uses balloon counter-pulsation technology to reduce the workload of the heart’s left ventricle, relieving heart failure symptoms. The product is similar to a pacemaker in that the balloon inflation and deflation synchronizes with the patient’s heartbeat. ’This is our sole product, so from our standpoint we are primarily a single medical device company and this is what we’re focused on,’ said Sunshine Heart CFO Jeff Mathiesen.
